Novel oral histone deacetylase inhibitor, MPT0E028, displays potent growth-inhibitory activity against human B-cell lymphoma in vitro and in vivo

Histone deacetylase (HDAC) inhibitor has been a promising therapeutic option in cancer therapy due to its ability to induce growth arrest, differentiation, and apoptosis. In this study, we demonstrated that MPT0E028, a novel HDAC inhibitor, reduces the viability of B-cell lymphomas by inducing apopt...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncotarget
Autors principals: Huang, Han-Li, Peng, Chieh-Yu, Lai, Mei-Jung, Chen, Chun-Han, Lee, Hsueh-Yun, Wang, Jing-Chi, Liou, Jing-Ping, Pan, Shiow-Lin, Teng, Che-Ming
Format: Artigo
Idioma:Inglês
Publicat: Impact Journals LLC 2014
Matèries:
Research Paper
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4467128/
https://ncbi.nlm.nih.gov/pubmed/25669976
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars